Mesenchymal stem cells may be efficiently obtained from a biological cell sample containing mesenchymal stem cells by: (1) culturing the biological cell sample containing mesenchymal stem cells in a serum-free medium in the presence of vitronectin or a partial peptide thereof capable of adhering mesenchymal stem cells, and (2) collecting a cell aggregate of the mesenchymal stem cells.

The present disclosure provides methods of introducing site-specific mutations in a target cell and methods of determining efficacy of enzymes capable of introducing site-specific mutations. The present disclosure also provides methods of providing a bi-allelic sequence integration, methods of integrating of a sequence of interest into a locus in a genome of a cell, and methods of introducing a stable episomal vector in a cell. The present disclosure further provides methods of generating a human cell that is resistant to diphtheria toxin.

Disclosed herein are platforms, systems, and methods including a cell culture system that includes a cell culture container comprising a cell culture, the cell culture receiving input cells, a cell imaging subsystem configured to acquire images of the cell culture, a computing subsystem configured to perform a cell culture process on the cell culture according to the images acquired by the cell imaging subsystem, and a cell editing subsystem configured to edit the cell culture to produce output cell products according to the cell culture process.

Disclosed herein are cell processing systems, devices, and methods thereof. A system for cell processing may comprise a plurality of instruments each independently configured to perform one or more cell processing operations upon a cartridge, and a robot capable of moving the cartridge between each of the plurality of instruments.

Provided herein are compositions comprising populations of cells obtained from a pregnant subject comprising at least one of a Hofbauer cell, a cytotrophoblast, a syncytiotrophoblast, an extravillous trophoblast, a villous core stroma, or a fetal vascular cell; a stabilization buffer, wherein the stabilization buffer comprises a preservative; and a cellulosic collection device, wherein at least a subset of the population of cells are intact and inviable and methods of making and using such compositions.

A method and apparatus of aseptic processing and production of cells in a non-sterile enclosure apparatus without chemical biocides is disclosed, by controlling the level of humidity throughout the enclosure to 25% relative humidity (RH) or less, and preferably 20% or 15% or less RH. In addition, the temperature is controlled to 37° C., and consistent gas flow is maintained the enclosure. Colony forming units from microbial contamination detected by environmental monitoring within the enclosure are significantly reduced in this method.

Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetically modified T cell receptors, and other genetic modifications, and uses of such expanded and/or modified PBLs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.

Provided is a cell culture apparatus including a culture vessel that stores a cell suspension containing cells; a first filter part that has a first filter membrane that performs membrane separation treatment on the cell suspension extracted from the culture vessel; a first circulation flow path that allows components blocked by the first filter membrane to return to the culture vessel; a second filter part that has a second filter membrane that performs membrane separation treatment on components of the cell suspension permeated through the first filter membrane; a second circulation flow path that allows components permeated through the second filter membrane to return to the culture vessel; and a recovery flow path that recovers components blocked by the second filter membrane. In the cell culture apparatus, an average hole diameter of the first filter membrane is 20 μm or smaller, and 0<B/A≤0.5 is satisfied in a case where an average hole diameter of the first filter membrane is A and an average hole diameter of the second filter membrane is B; or an average hole diameter of the first filter membrane is 20 μm or smaller, and the second filter membrane is an ultrafiltration membrane.

A broad object of a the instant invention can be to provide a method for separating X and Y sperm cells within a sample sperm cell population, the method including (i) differentiating between and (ii) separating sperm cells that have undergone a cellular process and sperm cells that have not undergone the cellular process, whereby a majority of the sperm cells that have undergone the cellular process can comprise one of X or Y sperm cells, and a majority of the sperm cells that have not undergone the cellular process can comprise the other of X or Y sperm cells. As to particular embodiments, the cellular process can be a maturational step. As to particular embodiments, the maturational step can be capacitation. As to particular embodiments, the maturational step can be the acrosome reaction. As to particular embodiments, non-viable and viable sperm cells can also be (i) differentiated between and (ii) separated.

Solutions to the problem of the invention are a method for selectively killing or removing a senescent cell, substance identification, and a method for purifying a senescent cell. Specifically, the invention includes an agent for removing a senescent cell, which is a drug for removing an in vivo senescent cell, the agent containing an inhibitor for glutaminase as an active ingredient, and a pharmaceutical composition containing the agent. The invention further includes a method for preparing a senescent cell, including the following steps (a) to (c): (a) synchronizing a cell with the G2 phase; (b) activating an intracellular p53 protein in the cell synchronized with the G2 phase; and (c) inhibiting polo-like kinase 1 (PLK1) activity in the cell treated in the step (b).